BTH I have read a few internet postings by patients on ponatinib.
They are very positive, as you said they would be.
The following is an excerpt from a post by a patient in the PACE trial:
>You might be interested in the following: I emailed Dr. Jorge Cortes at MD Anderson, one of the principal investigators on the Phase I trial, to ask if there have there been any patients taking ponatinib who achieved a complete response and subsequently developed resistance to it. He replied this morning:
We have seen occasional patients lose their response to ponatinib. The risks appear to be higher for patients treated in the more advanced stages of the disease.<
I had been wondering, and posted it here, if using ponatinib early on might be way advantageous.
News 
Market Data 
Discover 
AI
